What do systematic reviews say?

Tenofovir‐based antiviral combination regimens vs placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens

It is very uncertain whether tenofovir‐based antiviral combination regimens changes all‐cause infant mortality at longest compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).

• Antivirals for prevention of hepatitis B virus mother‐to‐child transmission in human immunodeficiency virus positive… 2023 · Cochrane Headline outcomes only
  RR 2.24 [0.72, 6.96]
  1 study · 132 participants
  Very low

Tenofovir‐based antiviral combination regimens vs placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens

It is very uncertain whether tenofovir‐based antiviral combination regimens changes proportion of infants with serious adverse events ( compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).

• Antivirals for prevention of hepatitis B virus mother‐to‐child transmission in human immunodeficiency virus positive… 2023 · Cochrane Headline outcomes only
  RR 1.76 [1.27, 2.43]
  1 study · 132 participants
  Very low

Tenofovir‐based antiviral combination regimens vs placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens

• Antivirals for prevention of hepatitis B virus mother‐to‐child transmission in human immunodeficiency virus positive… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Tenofovir‐based antiviral combination regimens vs placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens

• Antivirals for prevention of hepatitis B virus mother‐to‐child transmission in human immunodeficiency virus positive… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Tenofovir‐based antiviral combination regimens vs placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens

It is very uncertain whether tenofovir‐based antiviral combination regimens changes proportion of mothers with serious adverse events ( compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).

• Antivirals for prevention of hepatitis B virus mother‐to‐child transmission in human immunodeficiency virus positive… 2023 · Cochrane Headline outcomes only
  RR 0.9 [0.62, 1.32]
  2 studies · 270 participants
  Very low